ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1532

The Non-psychotropic Phytocannabinoids Cannabigerol and Tetrahydrocannabinolic Acid Inhibit Rheumatoid Arthritis Synovial Fibroblast Function by Targeting the Wasabi Receptor TRPA1

Torsten Lowin1, Matthias Schneider2 and Georg Pongratz3, 1Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Düsseldorf, Germany, 2Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany, 3Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, D�sseldorf, Germany

Meeting: ACR Convergence 2020

Keywords: Cell Death, cytokines, Fibroblasts, Synovial, immunology, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Cytokines & Cell Trafficking Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: While medical cannabis is available for german patients since 2017, its use to alleviate symptoms of rheumatic diseases is not recommended due to a lack of clinical studies. While cannabis might be beneficial to treat neuropathic pain, the impact on inflammation has not been assessed adequately. In this study, we investigated the effects of the two non-psychotropic plant cannabinoids, cannabigerol (CBG) and tetrahydrocannabinolic acid (THCA) on the function of rheumatoid arthritis synovial fibroblasts (RASF).

Methods: RASF were treated with THCA and CBG together with TNF or vehicle. After three days, proliferation and cytokine production (IL-6, IL-8 and MMP-3) were assessed. Furthermore, intracellular calcium mobilization and cell death were investigated.

Results: CBG and THCA decreased the proliferation of RASF in vitro (p< 0.001), which was dependent on concentration of cannabinoids and fetal calf serum content of the culture medium. This was accompanied by reduced production of IL-6, IL-8 and MMP-3 (p< 0.001). CBG and THCA increased intracellular calcium (p< 0.001) levels and the uptake of the viability dye PoPo3 (p< 0.001), which was inhibited by antagonizing the wasabi receptor TRPA1 (transient receptor potential type ankyrin). In addition, we observed significant cell death in response to THCA and CBG, which was inhibited by the mitochondrial transition pore inhibitor cyclosporin A. In contrast to TNF pre-stimulated RASF, the effects of CBG and THCA on cytokine production, proliferation, cell death and calcium mobilization were absent or less pronounced in unstimulated RASF.

Conclusion: CBG and THCA showed robust anti-inflammatory effects preferentially in TNF-activated RASF by targeting the wasabi receptor TRPA1. This ion channel might be a novel therapeutic target since it exerts a crucial influence on the function of RASF, which, in vivo contribute to the pro-inflammatory environment in the rheumatoid joint.


Disclosure: T. Lowin, None; M. Schneider, GSK, UCB, Abbvie, 2, Abbvie, Alexion, Astra Zeneca, BMS, Boehringer Ingelheim, Gilead, Lilly, Sanofi, UCB, 5, Abbvie, Astra Zeneca, BMS, Chugai, GSK, Lilly, Pfizer, Sanofi, 8; G. Pongratz, None.

To cite this abstract in AMA style:

Lowin T, Schneider M, Pongratz G. The Non-psychotropic Phytocannabinoids Cannabigerol and Tetrahydrocannabinolic Acid Inhibit Rheumatoid Arthritis Synovial Fibroblast Function by Targeting the Wasabi Receptor TRPA1 [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-non-psychotropic-phytocannabinoids-cannabigerol-and-tetrahydrocannabinolic-acid-inhibit-rheumatoid-arthritis-synovial-fibroblast-function-by-targeting-the-wasabi-receptor-trpa1/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-non-psychotropic-phytocannabinoids-cannabigerol-and-tetrahydrocannabinolic-acid-inhibit-rheumatoid-arthritis-synovial-fibroblast-function-by-targeting-the-wasabi-receptor-trpa1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology